Results 101 to 110 of about 1,204 (125)

Real-world experience with efgartigimod in generalized myasthenia gravis: a single-center retrospective study in China. [PDF]

Front Immunol
Niu Z, Wang J, Ren J, Liu R, Guo J, Zhang N, Zheng Y, Hao H, Gao F, Jin H.   +9 more
europepmc   +1 more source

Severe Hypogammaglobulinemia (IgG) During Efgartigimod Therapy in Neurological Practice: A Real-World Case Series. [PDF]

Cureus
Espinosa PS, Preisler J, Motiño Villanueva A, Bellon MB, Hennekens CH.   +4 more
europepmc   +1 more source

Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Yasuda M, Uzawa A, Handa H, Ogaya E, Kurumada K, Takasaka K, Mori M, Kuwabara S.   +7 more
europepmc   +1 more source

Efgartigimod as Rescue Therapy for PD-1 Inhibitor-Associated Myasthenia Gravis, Myocarditis, and Myositis (MMM) Syndrome: A 2-Case Report and Literature Review. [PDF]

Am J Case Rep
Liu ZH, Duan LM, Fang XZ, Jiang W, Sun SW, Shang Y, Huang CL, Yuan Y.   +7 more
europepmc   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study. [PDF]

Muscle Nerve
Lin J, Qi G, Luo S, Jiang Q, Bu B, Liu M, Wei Y, Han M, Yang J, Zhao Z, Zhang L, Zhang Y, Xu H, Hao X, Li Z.   +14 more
europepmc   +1 more source

Efficacy and safety of efgartigimod in the treatment of impending myasthenic crisis. [PDF]

Front Immunol
Li N, Zhang Y, Liu L, Jin Y, Zhao L, Zhu S, Li Y, Ma B, Peng J, Yang J, Li Q, Yang X.   +11 more
europepmc   +1 more source

The Fiscal Consequences for the Canadian Government of Efgartigimod in the Treatment of Generalized Myasthenia Gravis. [PDF]

J Health Econ Outcomes Res
Paquete AT, Connolly MP, Qi C, Katzberg H, Raza S, Kassardjian C, Siddiqi ZA, Kaprielian R, Locklin J, Phillips GA, Kotsopoulos N.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience

Expert Review of Clinical Immunology, 2022
Rosangela Gomes, Jessica Barreto Ribeiro dos Santos, Michael Ruberson Ribeiro da Silva   +2 more
exaly  

Clinical Efficacy and Safety of Efgartigimod for Treatment of Myasthenia Gravis

Immunotherapy, 2023
Ajith Sivadasan, Vera Bril
exaly